Latest Videos |view all videos
Ruben A. Mesa, M.D., discusses of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients
Dr. Robert Foote comments on findings of a new study by radiation oncologists at Mayo Clinic comparing the world's literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base.
Jakub James, M.D. demonstrates the operative technique of minimally invasive inguinal lymph node dissection in patients with melanoma. This video is intended for a surgical audience and is not intended to replace hands on training.
Igor Frank, M.D., discusses surgical treatment options for patients with prostate cancer.
Dr. Smoot describes treatment options and the specialized team of experts at Mayo Clinic who provide care for patients with cholangiocarcinoma.
R. Jeffrey Karnes, M.D., Consultant and Associate Professor, Mayo Clinic, discusses treatment options for bladder cancer. The ailment can be subdivided into sub categories and the treatments dramatically differ. Invasive treatments can ...
Jon Ebbert, M.D., of the Mayo Clinic Nicotine Dependence Center, on a study combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, that resulted in higher smoking abstinence rates.
Richard Hurt, M.D., Director of Mayo Clinic's Nicotine Dependence Center, comments on a new report by the Surgeon General released Jan. 2014 The Health Consequences of Smoking -- 50 Years of Progress that highlights a half a century of ...
Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC) and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Alan P. Fields, Ph.D., Monica Flynn Jacoby Professor of Cancer Studies at Mayo Clinic in Florida, talks about the publication of his team's latest discovery.
A study published today in the journal BMJ says annual screening mammograms in women aged 40-59 do not reduce deaths from breast cancer any better than a physical examination or usual care.
Panagiotis Anastasiadis, Ph.D. presents Targeting Polarity Pathways for Cancer Treatment